Table 1.
Samples of participants included in cross-sectional analysis.
| Site | Categorya | LRb | Timepointc | Number |
|---|---|---|---|---|
| Bangladesh | EC | na | na | 61 |
| BB/BL/LL (MB) no LR t = 0 | no LR | t = 0 | 62 | |
| BB/BL/LL (MB) no LR t = end | no LR | t = end | 26 | |
| TT/BT (PB) no LR t = 0 | no LR | t = 0 | 36 | |
| TT/BT (PB) no LR t = end | no LR | t = end | 9 | |
| BB/BL/LL (MB) RR t = 0 | RR | t = 0 | 5 | |
| BB/BL/LL (MB) RR t = x | RR | t = x | 30 | |
| BB/BL/LL (MB) RR t = end | RR | t = end | 42 | |
| TT/BT (PB) RR | RR | t = 0 or = x, or = end | 9 | |
| ENL/Neuritis | ENL/Neuritis | t = 0 or = x, or = end | 11/0 | |
| HHC | na | na | 38 | |
| Brazil | EC | na | na | 46 |
| BB/BL/LL (MB) no LR t = 0 | no LR | t = 0 | 26 | |
| BB/BL/LL (MB) no LR t = end | no LR | t = end | 20 | |
| TT/BT (PB) no LR t = 0 | no LR | t = 0 | 52 | |
| TT/BT (PB) no LR t = end | no LR | t = end | 38 | |
| BB/BL/LL (MB) RR t = 0 | RR | t = 0 | 17 | |
| BB/BL/LL (MB) RR t = x | RR | t = x | 20 | |
| BB/BL/LL (MB) RR t = end | RR | t = end | 20 | |
| TT/BT (PB) RR | RR | t = 0 or = x, or = end | 28 | |
| ENL or Neuritis | ENL/Neuritis | t = 0 or = x, or = end | 22/18 | |
| HHC | na | na | 14 | |
| Ethiopia | EC | na | na | 51 |
| BB/BL/LL (MB) no LR t = 0 | no LR | t = 0 | 83 | |
| BB/BL/LL (MB) no LR t = end | no LR | t = end | 9 | |
| TT/BT (PB) no LR t = 0 | no LR | t = 0 | 16 | |
| TT/BT (PB) no LR t = end | no LR | t = end | 1 | |
| BB/BL/LL (MB) RR t = 0 | RR | t = 0 | 2 | |
| BB/BL/LL (MB) RR t = x | RR | t = x | 36 | |
| BB/BL/LL (MB) RR t = end | RR | t = end | 12 | |
| TT/BT (PB) RR | RR | t = 0 or = x, or = end | 6 | |
| ENL or Neuritis | ENL/Neuritis | t = 0 or = x, or = end | 11/1 | |
| HHC | na | na | 33 | |
| Nepal | EC | na | na | 42 |
| BB/BL/LL (MB) no LR t = 0 | no LR | t = 0 | 14 | |
| BB/BL/LL (MB) no LR t = end | no LR | t = end | 5 | |
| TT/BT (PB) no LR t = 0 | no LR | t = 0 | 19 | |
| TT/BT (PB) no LR t = end | no LR | t = end | 8 | |
| BB/BL/LL (MB) RR t = 0 | RR | t = 0 | 6 | |
| BB/BL/LL (MB) RR t = x | RR | t = x | 12 | |
| BB/BL/LL (MB) RR t = end | RR | t = end | 7 | |
| TT/BT (PB) RR | RR | t = 0 or = x, or = end | 29 | |
| ENL or Neuritis | ENL/Neuritis | t = 0 or = x, or = end | 2/0 | |
| HHC | na | na | 6 | |
| Netherlands | NEC first time point | na | na | 19 |
| NEC second time points | na | na | 10 | |
| total | 1090 |
aEC: endemic control; BB/BL/LL: borderline borderline/borderline lepromatous/lepromatous leprosy; TT/BT: tuberculoid leprosy/borderline tuberculoid leprosy; bLR: leprosy reaction; RR: reversal reaction; NEC: non-endemic control; na: not applicable; ct = 0: time point of enrolment before initiation of multidrug (MDT) therapy; t = x: time point of LR; t = end: time point of completion of MDT and/or steroid therapy.